Bittenbring, Jörg Thomas <br/><br/>
Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2014 
 - 3242-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2013.53.4537  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Calcifediol--blood<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Prednisone--administration & dosage<br/>Risk Factors<br/>Rituximab<br/>Treatment Outcome<br/>Vincristine--administration & dosage<br/>Vitamin D Deficiency--complications